Parion Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Parion Sciences, Inc.
Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis
Drug Discovery Tools
- Drug Discovery Tools